Research Report on Paradigm Biopharmaceuticals.
The report contains:
- Analyst commentary on Paradigm Biopharmaceuticals’ Pentosan Polysulfate Sodium (PPS) drug
- Summary of the Hayfever & Bone Marrow Edema (BME) markets
- Baker Young’s view on Paradigms’s share price drivers for CY2016
- Valuation and Share Price target
- 10 Reasons to Invest in Paradigm Biopharmaceuticals
Please enter your details below to get the report sent to your email address: